{
    "clinical_study": {
        "@rank": "55228", 
        "arm_group": {
            "arm_group_label": "Simotinib Treatment", 
            "arm_group_type": "Experimental", 
            "description": "\"3+3\" design, ascending multiple doses. Simotinib Hydrochloride: 100mg, 200mg, 300mg, 400mg, 500mg, bid, for 28 days"
        }, 
        "brief_summary": {
            "textblock": "The primary objective is to assess the safety and tolerability of multiple doses of\n      Simotinib Hydrochloride in NSCLC patients. The secondary objective is to determine the\n      pharmacokinetic (PK) profile and explore the preliminary anti-tumor activity."
        }, 
        "brief_title": "Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically or cytologically confirmed diagnosis of advanced NSCLC,\n             who were previously treated with at least one platinum-based chemotherapy regimen,\n             but had disease relapse;\n\n          -  Patients have ended their chemotherapy or radiotherapy at least 4 weeks prior to\n             study entry and have recovered from any previous toxicity;\n\n          -  EGFR mutation positive (such as E19del\u3001L858R\u3001L861Q\u3001G719X, etc.);\n\n          -  Patients with at least one measurable lesion meeting RECIST;\n\n          -  ECOG performance status 0-2;\n\n          -  Life expectancy \u226512 weeks;\n\n          -  Adequate bone marrow function: ANC \u22651.5 \u00d7 109/L, PLT\u226580 \u00d7109/L, HB \u226590 g/L;\n\n          -  Adequate hepatic function: serum bilirubin \u2264 2 \u00d7 ULN, AST and ALT \u2264 2.5 \u00d7 ULN, and \u2264\n             5 \u00d7 ULN are acceptable if the liver has tumor involvement;\n\n          -  Adequate renal function: endogenous creatinine clearance rate (CrCl) \u2265 60 mL/min or\n             serum creatinine \u2264 1.5 \u00d7 ULN;\n\n          -  Females with childbearing potential must have a negative pregnancy test within 7 days\n             prior to treatment and use an approved contraceptive method during the study;\n\n          -  Males must be surgically sterile or use an approved contraceptive method during the\n             study.\n\n        Exclusion Criteria:\n\n          -  Patients who were previously treated by EGFR inhibitor or other molecular targeting\n             drugs (micromolecular drugs or monoclonal antibodies) such as Iressa, Tarceva,\n             Sutent, Nexavar, Sprycel, Erbitux, Nimotuzumab, Icotinib, Herceptin, etc.;\n\n          -  The known hypersensitivity to Simotinib or any of the excipients;\n\n          -  Concurrent treatment with rifampin, rifabutin, rifapentine, dexamethasone, phenytoin\n             sodium, carbamazepine, phenobarbital, Hypericum perforatum, atazanavir,\n             clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir,\n             ritonavir, saquinavir, and telithromycin;\n\n          -  CNS metastasis diagnosed recently which has not received surgery or radiotherapy;\n\n          -  Evidence of  interstitial lung disease;\n\n          -  Pre-existing idiopathic pulmonary fibrosis as evidenced by CT scan at baseline;\n\n          -  Any serious or uncontrollable systemic disease (such as unstable respiratory\n             disorders, cardiovascular, hepatic or kidney disorders);\n\n          -  Any unstable systemic disorders (including active infection, uncontrollable\n             hypertension, unstable angina pectoris, congestive heart failure, liver and kidney\n             disorders or metabolism disease);\n\n          -  Other malignancies diagnosed within the last 5 years with the exception of completely\n             cured cervical cancer in situ, or basal and squamous cell skin cancer;\n\n          -  Any remarkable eye disorders, especially severe dry eye syndrome,\n             keratoconjunctivitis sicca, herpes keratitis;\n\n          -  History of nerve or psychiatric disorders, including epilepsy or dementia."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772732", 
            "org_study_id": "SIM-101-1"
        }, 
        "intervention": {
            "arm_group_label": "Simotinib Treatment", 
            "intervention_name": "Simotinib Hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Simotinib", 
            "Non-small Cell Lung Cancer"
        ], 
        "lastchanged_date": "August 21, 2013", 
        "location": {
            "contact": {
                "last_name": "Yuankai Shi, MD", 
                "phone": "86-10-87788268"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)", 
        "overall_contact": {
            "last_name": "Yuankai Shi, MD", 
            "phone": "86-10-87788268"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
            "last_name": "Yuankai Shi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum tolerated dose (MTD)", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772732"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "d1,d8,d9,d10,d15"
            }, 
            {
                "measure": "The time to Cmax (tmax)", 
                "safety_issue": "No", 
                "time_frame": "d1,d8,d9,d10,d15"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "d1,d8,d9,d10,d15"
            }, 
            {
                "measure": "Overall Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "measure": "Progression-free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Simcere Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}